Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for ruptured liver cancer: drug combo aims to prevent return

NCT ID NCT07331883

First seen Jan 12, 2026 · Last updated May 18, 2026 · Updated 19 times

Summary

This study tests whether a combination of two drugs (sintilimab and bevacizumab biosimilar) can help prevent liver cancer from coming back after surgery in people whose tumor had ruptured. About 35 adults with this high-risk condition will receive the treatment. The goal is to see if this approach is safe and improves how long patients live without the cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200031, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sanming First Hospital

    NOT_YET_RECRUITING

    Sanming, Fujian, 365000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Third Bethune Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130033, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.